SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 2nd, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 29, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco:CNS Pharmaceuticals, Inc. • February 2nd, 2024 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”), Maxim Group LLC (“Maxim” and together with A.G.P., the “Placement Agents”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), that the Placement Agents shall serve as the exclusive placement agents for the Company, on a reasonable “best efforts” basis, in connection with the proposed placement (the “Placement”) of (i) shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), (ii) warrants (the “Common Warrants”) to purchase shares of Common Stock (the “Common Warrant Shares”) and (iii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares and Common Warrants, the “Securities”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”). The Securities actually placed by the Placement Agents are referred to herein as the “Placement Agents Securities.” The terms of the Placement shall be m
AMENDMENT TO COMMON STOCK PURCHASE WARRANTSCommon Stock Purchase Warrants • February 2nd, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of January 29, 2024, by and between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and _______ (the “Holder”).
